Table II.
Excluded papers and reasons for exclusion
| No. | Authors | Title | COVID-19 Yes/no |
Reason for exclusion |
|---|---|---|---|---|
| 1 | Chughtai et al., 2020 | Policies on the use of respiratory protection for hospital health workers to protect from coronavirus disease (COVID-19) | Yes | No details on therapeutics/commentary |
| 2 | Gurwitz, 2020 | Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics | Yes | Commentary |
| 3 | Wang et al., 2020 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Yes | Commentary |
| 4 | Colson et al., 2020 | Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 | Yes | Commentary |
| 5 | Liu et al., 2020 | Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy | Yes | No details on therapeutics/commentary |
| 6 | Baron et al., 2020 | Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? | Yes | Commentary |
| 7 | Mitja and Clotet, 2020 | Use of antiviral drugs to reduce COVID-19 transmission | Yes | Commentary |
| 8 | Colson et al., 2020 | Chloroquine for the 2019 novel coronavirus SARS-CoV-2 | Yes | Commentary |
| 9 | Morse et al., 2020 | Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV | Yes | Commentary |
| 10 | Thevarajan et al., 2020 | Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 | Yes | Commentary |
| 11 | Elfiky, 2020 | Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 | Yes | Commentary |
| 12 | Ung, 2020 | Community pharmacist in public health emergencies: quick to action against the coronavirus 2019-nCoV outbreak | Yes | Commentary |
| 13 | Gupta, 2020 | Clinical considerations for patients with diabetes in times of COVID-19 epidemic | Yes | Commentary |
| 14 | Dong et al., 2020 | Discovering drugs to treat coronavirus disease 2019 (COVID-19) | Yes | Commentary |
| 15 | Zhang et al., 2020 | Liver injury in COVID-19: management and challenges | Yes | Commentary |
| 16 | Cunningham et al., 2020 | Treatment of COVID-19: old tricks for new challenges | Yes | Commentary |
| 17 | Ko et al., 2020 | Arguments in favour of remdesivir for treating SARS-CoV-2 infections | Yes | Commentary |
| 18 | Arabi et al., 2020 | COVID-19: a novel coronavirus and a novel challenge for critical care | Yes | Commentary |
| 19 | Wang and Shi, 2020 | Managing neonates with respiratory failure due to SARS-CoV-2 | Yes | Commentary |
| 20 | Stebbing et al., 2020 | COVID-19: combining antiviral and anti-inflammatory treatments | Yes | Commentary |
| 21 | Touret and Lamballerie, 2020 | Of chloroquine and COVID-19 | Yes | Commentary |
| 22 | Porcheddu et al., 2020 | Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China | Yes | No therapeutic data/commentary |
| 23 | Zhang et al., 2020 | Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics | Yes | Commentary |
| 24 | Baden and Rubin, 2020 | COVID-19 – the search for effective therapy | Yes | Commentary |
| 25 | Baud et al., 2020 | COVID-19 in pregnant women | Yes | No therapeutic data/commentary |
| 26 | Ortega et al., 2020 | Unrevealing sequence and structural features of novel coronavirus using in silico approaches: the main protease as molecular target | Yes | No therapeutic data |
| 27 | Ma et al., 2020 | 2019 novel coronavirus disease in hemodialysis (HD) patients: report from one HD center in Wuhan, China | Yes | No therapeutic data |
| 28 | Columbus et al., 2020 | 2019 novel coronavirus: an emerging global threat | Yes | Commentary |
| 29 | Barry et al., 2020 | COVID-19 in the shadows of MERS-CoV in the Kingdom of Saudi Arabia | Yes | Commentary |
| 30 | Wang et al., 2020 | A precision medicine approach to managing 2019 novel coronavirus pneumonia | Yes | No therapeutic data/commentary |
| 31 | Singhal, 2020 | A Review of coronavirus disease-2019 (COVID-19) | Yes | Review article |
| 32 | Li et al., 2020 | A simple laboratory parameter facilitates early identification of COVID-19 patients | Yes | Retrospective case-negative control study |
| 33 | Guo et al., 2020 | A survey for COVID-19 among HIV/AIDS patients in two districts of Wuhan, China | Yes | No therapeutic data |
| 34 | Gao et al., 2020 | Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies | Yes | Commentary |
| 35 | Deng et al., 2020 | Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study | Yes | Retrospective control study |
| 36 | Murthy et al., 2020 | Care for critically ill patients with COVID-19 | Yes | Commentary |
| 37 | Deng and Peng, 2020 | Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China | Yes | Review |
| 38 | Wang et al., 2020 | Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China | Yes | No therapeutic data |
| 39 | Xiong et al., 2020 | Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes | Yes | No therapeutic data |
| 40 | Chen et al., 2020 | Clinical and immunologic features in severe and moderate forms of coronavirus disease 2019 | Yes | No therapeutic data |
| 41 | Chen et al., 2020 | Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records | Yes | No therapeutic data |
| 42 | Hong et al., 2020 | Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children | Yes | Perspectives/no therapeutic data |
| 43 | Ye et al., 2020 | Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation | Yes | No therapeutic data |
| 44 | Anderson et al., 2020 | Clinical management of suspected or confirmed COVID-19 disease | Yes | Review |
| 45 | Zhang et al., 2020 | Clinical trials for the treatment of coronavirus disease 2019 (COVID-19): a rapid response to urgent need | Yes | Commentary |
| 46 | Chen et al., 2020 | Convalescent plasma as a potential therapy for COVID-19 | Yes | Commentary |
| 47 | Yang et al., 2020 | Corona virus disease 2019: a growing threat to children? | Yes | Commentary/no therapeutic data |
| 48 | Kooraki et al., 2020 | Coronavirus (COVID-19) outbreak: what the department of radiology should know | Yes | Commentary/no therapeutic data |
| 49 | Rasmussen et al., 2020 | Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to know | Yes | Commentary/no therapeutic data |
| 50 | Liu et al., 2020 | Coronavirus disease 2019 (COVID-19) during pregnancy: a case series | Yes | No therapeutic data |
| 51 | Mclntosh et al., 2020 | Coronavirus disease 2019 (COVID-19) | Yes | Review |
| 52 | He and Li, 2020 | Coronavirus disease 2019 (COVID-19): what we know? | Yes | Review |
| 53 | Xiong et al., 2020 | Coronaviruses and the cardiovascular system: acute and long-term implications | Yes | Commentary |
| 54 | Gong et al., 2020 | Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia | Yes | No therapeutic data |
| 55 | Dong et al., 2020 | Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China | Yes | No therapeutic data |
| 56 | Shereen et al., 2020 | COVID-19 infection: origin, transmission, and characteristics of human coronaviruses | Yes | Review |
| 57 | Rio and Malani, 2020 | COVID-19 – new insights on a rapidly changing epidemic | Yes | Review |
| 58 | Yi et al., 2020 | COVID-19: what has been learned and to be learned about the novel coronavirus disease | Yes | Review |
| 59 | Rezaeetalab et al., 2020 | COVID-19: a new virus as a potential rapidly spreading in the worldwide | Yes | Review |
| 60 | Shaker et al., 2020 | COVID-19: pandemic contingency planning for the allergy and immunology clinic | Yes | No therapeutic data |
| 61 | Aslam and Mehra, 2020 | COVID-19: yet another coronavirus challenge in transplantation | Yes | Commentary |
| 62 | Padmanabhan, 2020 | Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with nitazoxanide and hydroxychloroquine | Yes | Commentary |
| 63 | Hick et al., 2020 | Duty to plan: health care, crisis standards of care, and novel coronavirus SARS-CoV-2 | Yes | Discussion |
| 64 | Yang et al., 2020 | Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China | Yes | No therapeutic data |
| 65 | Khan, 2020 | Epidemiology of corona virus in the world and its effects on the China economy | Yes | Review |
| 66 | Hoehl et al., 2020 | Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China | Yes | Commentary |
| 67 | Yang et al., 2020 | Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome | Yes | Review |
| 68 | Cascella et al., 2020 | Features, evaluation and treatment of coronavirus (COVID-19) | Yes | Review |
| 69 | Erol, 2020 | High-dose intravenous vitamin C treatment for COVID-19 (a mechanistic approach) | Yes | Review |
| 70 | Liu et al., 2020 | Highly ACE2 expression in pancreas may cause pancreas damage after SARS-CoV-2 infection | Yes | Commentary |
| 71 | Zhang et al., 2020 | Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19 | Yes | No therapeutic data |
| 72 | Mao et al., 2020 | Implications of COVID-19 for patients with pre-existing digestive diseases | Yes | Commentary |
| 73 | Ferguson et al., 2020 | Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand | Yes | No therapeutic data |
| 74 | Qiu et al., 2020 | Intensive care during the coronavirus epidemic | Yes | Commentary |
| 75 | Poon et al., 2020 | ISUOG interim guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals | Yes | Review |
| 76 | Khan et al., 2020 | The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options | Yes | Discussion |
| 77 | Sun et al., 2020 | Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province | Yes | Commentary |
| 78 | Guzzi et al., 2020 | Master regulator analysis of the SARS-CoV-2/human interactome | Yes | No therapeutic data |
| 79 | Memish et al., 2020 | Middle East respiratory syndrome | No | Review |
| 80 | Nicastri, 2020 | Recommendations for COVID-19 clinical management | Yes | Commentary |
| 81 | Li et al., 2020 | Network bioinformatics analysis provides insight into drug repurposing for COVID-2019 | Yes | No therapeutic data |
| 82 | Xiong et al., 2020 | Novel and potent inhibitors targeting DHODH, a rate-limiting enzymein de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2 | Yes | No therapeutic data |
| 83 | Rezabakhsh et al., 2020 | Novel coronavirus (COVID-19): a new emerging pandemic threat | Yes | Survey/no therapeutic data |
| 84 | Ai et al., 2020 | Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China | Yes | No therapeutic data |
| 85 | Qiu et al., 2020 | Outcome reporting from protocols of clinical trials of coronavirus disease 2019 (COVID-19): a review | Yes | No therapeutic data |
| 86 | Bajema et al., 2020 | Persons evaluated for 2019 novel coronavirus – United States, January 2020 | Yes | Commentary |
| 87 | Shanmugaraj et al., 2020 | Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19) | Yes | Review |
| 88 | Zhou and Zhao, 2020 | Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2 | Yes | Review |
| 89 | Hoffmann et al., 2020 | SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor | Yes | No therapeutic data |
| 90 | Zhang and Liu, 2020 | Potential interventions for novel coronavirus in China: a systematic review | Yes | Review |
| 91 | Vasylyeva, 2020 | Pregnancy and COVID-19: a brief review | Yes | Review |
| 92 | Alamri et al., 2020 | Pharmacoinformatics and molecular dynamic simulation studies reveal potential inhibitors of SARS-CoV-2 main protease 3CLpro | Yes | No therapeutic data |
| 93 | Fisher and Heymann, 2020 | Q&A: The novel coronavirus outbreak causing COVID-19 | Yes | Commentary |
| 94 | Goh et al., 2020 | Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from COVID-19 infection | Yes | No therapeutic data |
| 95 | Chen et al., 2020 | Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients | Yes | No therapeutic data |
| 96 | Bouadma et al., 2020 | Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists | Yes | Review |
| 97 | Zhu et al., 2020 | Systematic review of the registered clinical trials of coronavirus disease2019 (COVID-19) | Yes | Review |
| 98 | Yang et al., 2020 | The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China | Yes | Review |
| 99 | Li et al., 2020 | The neuroinvasive potential of SARS CoV2 may play a role in the respiratory failure of COVID 19 patients | Yes | Review |
| 100 | Naicker et al., 2020 | The novel coronavirus 2019 epidemic and kidneys | Yes | Review |
| 101 | Fang et al., 2020 | Transmission dynamics of the COVID 19 outbreak and effectiveness of government interventions: a data driven analysis | Yes | No therapeutic data |
| 102 | Sun et al., 2020 | Understanding of COVID 19 based on current evidence | Yes | Review |
| 103 | Wang et al., 2020 | Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures | Yes | Review |
| 104 | Maoujoud et al., 2020 | What nephrologist should know about COVID-19 outbreak? | Yes | Commentary |
| 105 | Cortegiani et al., 2020 | A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 | Yes | Review |
| 106 | Ryu et al., 2020 | An interim review of the epidemiological characteristics of 2019 novel coronavirus | Yes | Review |
| 107 | Yang and Shen, 2020 | Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19 | Yes | Review |
| 108 | Fan et al., 2020 | Bat coronaviruses in China | Yes | Review |
| 109 | Russell et al., 2020 | Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury | Yes | Commentary |
| 110 | Liang et al., 2020 | Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells | Yes | No therapeutic data/commentary |
| 111 | Wu et al., 2020 | Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China | Yes | Commentary |
| 112 | Martinez et al., 2020 | Compounds with therapeutic potential against novel respiratory 2019 coronavirus | Yes | Commentary |
| 113 | Tang et al., 2020 | Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient | Yes | No therapeutic data |
| 114 | Chang et al., 2020 | Coronavirus disease 2019: coronaviruses and blood safety | Yes | Review |
| 115 | Walker, 2020 | COVID-19, Australia: Epidemiology Report 2 | Yes | Commentary |
| 116 | Lu, 2020 | Drug treatment options for the 2019-new coronavirus (2019-nCoV) | Yes | Commentary |
| 117 | Hellewell et al., 2020 | Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts | Yes | No therapeutic data |
| 118 | Prompetchara et al., 2020 | Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic | Yes | Review |
| 119 | Ashour et al., 2020 | Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks | Yes | Review |
| 120 | Zhou et al., 2020 | Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 | Yes | No therapeutic data |
| 121 | Devaux et al., 2020 | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? | Yes | Review |
| 122 | Cauchi and Locht, 2020 | Non-specific effects of live attenuated pertussis vaccine against heterologous infectious and inflammatory diseases | Yes | Review |
| 123 | Chang et al., 2020 | Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking | Yes | No therapeutic data |
| 124 | Pang et al., 2020 | Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review | Yes | Review |
| 125 | Chen et al., 2020 | Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report | Yes | Commentary |
| 126 | Liu et al., 2020 | Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases | Yes | Review |
| 127 | Gralinski and Menachery, 2020 | Return of the coronavirus: 2019-nCoV | Yes | Commentary |
| 128 | Cao et al., 2020 | SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics | Yes | Commentary |
| 129 | Walls et al., 2020 | Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein | Yes | Commentary |
| 130 | Xu et al., 2020 | Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS- | Yes | Review |
| 131 | Garrett, 2020 | The art of medicine COVID-19: the medium is the message | Yes | Commentary |
| 132 | Habibzadeh and Stoneman, 2020 | The novel coronavirus: a bird's eye view | Yes | Review |
| 133 | Wu et al., 2020 | The SARS-CoV-2 outbreak: what we know | Yes | Review |
| 134 | Nezhad et al., 2020 | Therapeutic approaches for COVID-19 based on the dynamics of interferon-mediated immune responses | Yes | No therapeutic data |
| 135 | Lu, 2020 | Timely development of vaccines against SARS-CoV-2 | Yes | Commentary |
| 136 | Kim et al., 2020 | Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea | Yes | Commentary |
| 137 | Sekhar, 2020 | Virtual screening based prediction of potential drugs for COVID-19 | Yes | No therapeutic data |
| 138 | Park et al., 2020 | Virus isolation from the first patient with SARS-CoV-2 in Korea | Yes | Commentary |
| 139 | Lake, 2020 | What we know so far: COVID-19 current clinical knowledge and research | Yes | Review |
| 140 | Ralph et al., 2020 | 2019-nCoV (Wuhan virus), a novel coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness | Yes | Review |
| 141 | Jin, 2020 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) | Yes | Review |
| 142 | Liu et al., 2020 | Association of cardiovascular manifestations with in-hospital outcomes in patients with COVID-19: a hospital staff data | Yes | No therapeutic data |
| 143 | Lai et al., 2020 | Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths | Yes | Review |
| 144 | Bordi et al., 2020 | Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020 | Yes | Commentary |
| 145 | Li, 2020 | Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0) | Yes | Review |
| 146 | Song and Karako, 2020 | COVID-19: real-time dissemination of scientific information to fight a public health emergency of international concern | Yes | Commentary |
| 147 | Vankadari and Wilce, 2020 | Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 | Yes | Review |
| 148 | Hsih et al., 2020 | Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan | Yes | No therapeutic data |
| 149 | Stoecklin et al., 2020 | First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020 | Yes | No therapeutic data |
| 150 | Chan et al., 2020 | Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan | Yes | No therapeutic data |
| 151 | Boulos and Geraghty, 2020 | Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics | Yes | No therapeutic data |
| 152 | Zeng et al., 2020 | Mortality of COVID-19 is associated with cellular immune function compared to immune function in Chinese Han population | Yes | No therapeutic data |
| 153 | Ahmed et al., 2020 | Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies | Yes | No therapeutic data |
| 154 | Lai et al., 2020 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges | Yes | Review |
| 155 | Alhazzani et al., 2020 | Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) | Yes | No therapeutic data |
| 156 | Guo et al., 2020 | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status | Yes | Review |
| 157 | Yang et al., 2020 | Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective | Yes | Review |
| 158 | Liu et al., 2020 | Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction | Yes | No therapeutic data |
| 159 | World Health Organization, 2020 | Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected | Yes | Guidelines |
| 160 | Li et al., 2020 | Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis | Yes | No therapeutic data |
| 161 | Mao et al., 2020 | Clinical and pathological characteristics of 2019 novel coronavirus disease (COVID-19): a systematic reviews | Yes | Review |
| 162 | Cui et al., 2020 | Clinical features and sexual transmission potential of SARS-CoV-2 infected female patients: a descriptive study in Wuhan, China | Yes | No therapeutic data |
| 163 | Saw Swee Hock School of Public Health, 2020 | COVID-19 science report: therapeutics | Yes | Report |
| 164 | Yao, 2020 | In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Yes | Commentary |
| 165 | Pongpirul et al., 2020 | Journey of a Thai taxi driver and novel coronavirus | Yes | No therapeutic data |
| 166 | Liu et al., 2020 | A locally transmitted case of SARS-CoV-2 infection in Taiwan | Yes | No therapeutic data |
| 167 | Velavan and Meyer, 2020 | The COVID-19 epidemic | Yes | Commentary |